b'SIU OFFICE OF EDUCATIONClinical Pathway of BPH: Optimizing TreatmentLuncheon Symposium: Adjuvant Immunotherapy in Bladder and Decision-Making and Patient Care Kidney Cancers: A New Standard of Care for Our Patients?Chair: Stavros Gravas, Cyprus Co-Chairs: Panelists:Matthew Galsky, United StatesTian Zhang, United StatesNaeem Bhojani, CanadaNeal Rowe, Canada Panelists: Silvia Secco, Italy Umberto Capitanio, ItalyShilpa Gupta, United States Learning Objectives: Wassim Kassouf, CanadaAt the end of this symposium, participants should Learning Objectives:be able to:At the end of this symposium, participants should be able to: Examine the treatment options currently availableReview the most recent clinical practice guidelines on NMIBC,for patients with BPH MIBC, and RCC Recall the most recent clinical practice guidelinesRecognize the importance of risk stratification in the treatment and indications for treatment of LUTS associateddecision-making of bladder and kidney cancers with BPH Analyze emerging data from key clinical trials of adjuvant Recognize the importance of patient characteristicsimmunotherapies in NMIBC, MIBC, and localized RCC, with focusin treatment decision-making for BPH on immune checkpoint inhibitors Identify key steps underlying the surgical andDiscuss current challenges and opportunities with adjuvant immuno-minimally invasive management of BPH and therapy for improving patient outcomes, with respect to managing how to best perform them for optimal results treatment-related adverse events, follow-up, and patient quality of lifeSupported by Corporate Sponsor: Supported by Corporate Sponsor:Sessions From the Unaccredited ProgrammeSymposium: Individualized B2B Uro-Oncology Clinical B2B Uro-Oncology: GU B2B Uro-Oncology ClinicalCare for LUTS/BPE Patients Trial Spotlight: EV-302/EV-103 Cancers Triad Meeting: Trial Spotlight: CheckMate 274: in the Digital Era Cohort K: A Novel TreatmentExperts Highlights Insights from Extended Follow-Chair:Approach for AdvancedModerators: Up and Patient Quality of LifeDean Elterman, Canada Urothelial Carcinoma? Peter Black, Canada Expert:Panelists: Expert:Simon Tanguay, Canada Matthew Galsky, United States Stavros Gravas, Cyprus Srikala Sridhar, Canada Panelists:Interviewer:Claus Roehrborn, United States Interviewer: Peter Black, Canada Eugene Pietzak, United States Wassim Kassouf, Canada Learning Objectives Discussion Points:Lori Wood, Canada Discussion Points: At the end of this course, participants Key insights from emerging Martin Gleave, CanadaSummary of key insights from should be able to: data from phase 1/2 EV-103 Discussion Points: emerging data from the phase 3Understand how different patientcohort K trialSummary of key points CheckMate 274 trial profiles with LUTS/BPE respond to How results from EV-103 cohort Kdiscussed during the 4th B2BImplications of the extended follow-medical treatment, reinforcing theinform the ongoing phase 3 Uro-Oncology: GU Cancers up and health-related quality of life need of an individualized approachEV-302 trial Triad Meeting of CheckMate 274for optimal management What implications the resultsWhat are the implications offor the current clinical practiceDescribe and discuss recentof both trials may have for theemerging clinical data for the How updated results ofdevelopments in mobile healthtreatment landscape of advancedcurrent standard of care in CheckMate 274 support adjuvant urology apps, which may enableurothelial carcinoma GU oncology nivolumab therapy as a new better monitoring and outcomes Supported by Congress Contributor:How to best incorporatestandard of care in MIUC of LUTS/BPE patients advancements in the field intoSupported by Corporate Sponsor: Supported by Corporate Sponsor: practice within a multidisciplinary setting, with the aims of improving treatment outcomes andpatient careSupported by Corporate Sponsor: www.siu-urology.org 15'